Silbiotech, Inc

North Potomac, MD 20878

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $1.9MM
First Award Date 01/01/13
Most Recent Award Date 07/01/17

Key Personnel

Last Name Name Awards Contact
Poola Indira Poola 5 Message

4 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-270
Budget: 07/01/17 - 06/30/18

PROJECT SUMMARY / ABSTRACT This SBIR direct Phase II project is on developing a multimarker based technology for precisely selecting candidates for prophylactic treatments and preventing sporadic breast cancers. The patient population addressed here for selecting candidates is among subjects diagnosed with proliferative precancerous breast tumor...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 07/08/16 - 06/30/17

PROJECT SUMMARY / ABSTRACTThis SBIR direct Phase II project is on developing a multimarker based technology for precisely selectingcandidates for prophylactic treatments and preventing sporadic breast cancers.The patient population addressed here for selecting candidates is among subjects diagnosed with proliferativeprecancerous breast tumors th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 07/21/14 - 12/31/14

DESCRIPTION (provided by applicant): This Phase I research proposal is to investigate the feasibility of developing a novel Biomarker Breast PapTest for screening Nipple Aspirate Fluid (NAF) and detecting breast cancers at the tumor-in-formation stage before mammographically detectable tumors are developed. Although there is a slight decline i...

Phase 1 SBIR

Agency: National Science Foundation
Topic: BC-2012
Budget: 01/01/13 - 12/31/13

This Small Business Innovation Research (SBIR) Phase I project proposes to develop a breast cancer risk test for women who are diagnosed with breast atypical hyperplasias. Atypical hyperplasias of the breast are not cancers but are very high risk precancerous growths. Several studies have established that about 20-25% of women diagnosed with aty...